Summary: Bilastine is the newest second-generation antihistamine used in the symptomatic treatment of seasonal and perennial rhinitis, conjunctivitis, and urticaria. It is considered a very safe drug without sedative effect, and its safety in many groups of allergic patients, e.g. among minors, seniors and those burdened with multiple comorbidities with polypharmacy has been confirmed in many clinical trials. The drug does not penetrate the brain and does not impair psychomotor functions or cause drowsiness or fatigue. It has a very high safety profile for the patient. Bilastine starts working within 20–45 minutes of administration, is not metabolized in the body and is excreted unchanged, does not interact with any known drugs or alcohol.